| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
44 |
| Employees |
108 |
| Revenues (TTM) (Millions $) |
33 |
| Net Income (TTM) (Millions $) |
-35 |
| Cash Flow (TTM) (Millions $) |
-2 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Correvio Pharma Corp is a pharmaceutical company that specializes in developing and commercializing therapies to treat cardiovascular diseases, such as atrial fibrillation and acute coronary syndrome. The company is headquartered in Vancouver, Canada and operates globally.
Correvio's lead product is Brinavess (vernakalant hydrochloride), which is used to convert recent onset atrial fibrillation to normal sinus rhythm. Brinavess is approved in over 40 countries, primarily in Europe and Asia. The company is also developing a pipeline of other cardiovascular drugs, including Trevyent (treprostinil injection) for pulmonary arterial hypertension, and Zevtera (ceftobiprole medocaril) for the treatment of serious bacterial infections.
The company has an experienced management team and a strong focus on research and development. Its strategy is to develop innovative therapies for unmet medical needs in cardiovascular disease, while also seeking to expand its global reach through partnerships and collaborations.
Correvio has faced some challenges in recent years. In 2019, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter for Brinavess, requesting additional information related to the drug's safety profile. This setback has led the company to shift its focus towards the European and Asian markets, where Brinavess is already approved.
Overall, Correvio Pharma Corp is a well-established and reputable pharmaceutical company that is dedicated to improving the lives of those suffering from cardiovascular disease. Its strong research and development focus, experienced management team, and global reach make it a promising player in the industry.
|
%